Chronic progressive calcineurin nephrotoxicity: An overstated concept

American Journal of Transplantation

Volumn 11, Issue 4, 2011, Pages 687-692

  Matas, Arthur J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Calcineurin; nephrotoxicity

Indexed keywords

ANTIBODY; AZATHIOPRINE; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

CALCINEURIN INHIBITOR NEPHROTOXICITY; DELAYED GRAFT FUNCTION; DISEASE COURSE; DRUG INDUCED DISEASE; GLOMERULOSCLEROSIS; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; NEPHROTOXICITY; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; REVIEW;

CALCINEURIN; CHRONIC DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; RISK FACTORS;

EID: 79953254208     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03505.x     Document Type: Review

References (43)

1. Naesens M, Kuypers DRJ, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
2. Curtis JJ,. Cyclosporine-induced hypertension. In:, Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, diagnosis, and management. New York, NY: Raven Press, 1990: 1829-1835.
3. Kandaswamy R, Humar A, Casingal V, Gillingham KJ, Ibrahim H, Matas AJ,. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression. Transplantation 2007; 83: 722-726. (Pubitemid 46569189)
4. Gaston RS,. Chronic calcineurin inhibitor nephrotoxicity: Reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009; 4: 2029-2034.
5. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR,. Complete avoidance of calcineurin inhibitors in renal transplantaiton: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522. (Pubitemid 43382137)
6. Büchler M, Caillard S, Barbier S, et al,. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin®, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522-2531. (Pubitemid 47561618)
7. Glotz D, Charpentier B, Abramovicz D, et al,. Thymoblobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010; 89: 1511-1517.
8. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. ELITE-Symphony study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575. (Pubitemid 350294223)
9. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P,. A phase III study of Belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study). Am J Transplant 2010; 10: 535-546.
10. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J,. A phase III study of Belatacept versus cyclosporine in kidney transplants from extended donors (BENEFIT-EXT Study). Am J Transplant 2010; 10: 547-557.
11. Ekberg H, Grinyo J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A,. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR study. Am J Transplant 2007; 7: 560-570. (Pubitemid 46376436)
12. Gaston RS, Cecka JM, Kasiske BL, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
13. Meier-Kriesche H-U, Schold JD, Kaplan B,. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289-1295. (Pubitemid 39013575)
14. Nankivell BJ, Borrows RJ, Fung CL-S, O'Connell PJ, Allen RDM, Chapman J,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 24-33.
15. Nankivell BJ, Wavamunno MD, Borrows RJ, et al,. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant 2007; 7: 366-376. (Pubitemid 46096329)
16. Humar A, Hassoun A, Kandaswamy R, Payne W, Sutherland DER, Matas A,. Immunologic factors: The major risk for decreased long-term renal allograft survival. Transplantation 1999; 68: 1842-1846. (Pubitemid 30027334)
17. El-Zoghby ZM, Stegall MD, Lager DJ, et al,. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
18. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD,. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464-2472.
19. Matas AJ, Leduc R, Rush D, et al,. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: Preliminary data from the DeKAF study. Am J Transplant 2010; 10: 315-323.
20. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M,. Cyclosporine-associated chronic nephropathy. NEJM 1984; 311: 699-705. (Pubitemid 14074555)
21. Myers BD, Sibley R, Newton L, et al,. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590-600. (Pubitemid 18073785)
22. Ojo AO, Held PJ, Port FK, et al,. Chronic renal failure after transplantation of a nonrenal organ. NEJM 2003; 349: 931-940. (Pubitemid 37064766)
23. Hamour IM, Omar F, Lyster HS, Palmer A, Banner NR,. Chronic kidney disease after heart transplantation. Nephrol Dial Transplant 2009; 24: 1655-1662.
24. Navarro-Manchõn J, Martinez-Dolz, Bonet LA, et al,. Predictors of renal dysfunction at 1 year in heart transplant patients. Transplantation 2010; 89: 977-982.
25. Wagrowska-Danilewicz M, Danilewicz M, Sikorska B,. Glomerular and interstitial renal findings in patients with liver cirrhosis with normal renal function. The histomorphometric study. Gen Diagn Pathol 1996; 141: 353.
26. Axelsen RA, Crawford DHG, Endre ZH, et al,. Renal glomerular lesions in unselected patients with cirrhosis undergoing orthotopic liver transplantation. Pathology 1995; 27: 237-246.
27. McGuire BM, Julian GA, Bynon JS, et al,. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Int Med 2006; 144: 735-741. (Pubitemid 46780633)
28. Pillebout E, Nochy D, Hill G, et al,. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005; 5: 1120-1129. (Pubitemid 40571263)
29. Kim J-Y, Akalin E, Dikman S, et al,. The variable pathology of kidney disease after liver transplantation. Transplantation 2010; 89, 215-221.
30. Sanchez EQ, Melton LB, Chinnakotla S, et al,. Transplantation 2010; 89: 232-235.
31. Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer M,. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 115-117.
32. Bagnis CI, DuMontcel ST, Beaufils H, et al,. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: Follow-up study. J Am Soc Nephrol 2002; 13: 2962-2968. (Pubitemid 35386915)
33. Tappeiner C, Roesel M, Heinz C, Michels H, Ganser G, Heiligenhaus A,. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye 2009; 23: 1192-1198.
34. Ponticelli C,. Cyclosporine: From renal transplantation to autoimmune diseases. Ann NY Acad Sci 2005; 1051: 551-558. (Pubitemid 41362782)
35. Almond PS, Matas A, Gillingham K, et al,. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-756.
36. Rush D, Nickerson P, Gough J, et al,. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998; 9: 2129-2134. (Pubitemid 28482163)
37. Mannon RB, Matas AJ, Grande J, et al,. For the DeKAF Investigators. Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure. Am J Transplant 2010; 10: 2066-2073.
38. Halloran PF, de Freitas DG, Einecke G, et al,. An integrated view of molecular changes, histopathology, and outcomes in kidney transplants. Am J Transplant 2010; 10: 2223-2230.
39. Worthington JE, McEwen A, McWilliam LJ, Picton ML, Martin S,. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation 2007; 83: 398-403. (Pubitemid 46667842)
40. Terasaki PI, Cai J,. Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008; 86: 377-383.
41. Gibson IW, Gwinner W, Brocker, et al,. Peritubular capillaritis in renal allografts: Prevalence, scoring system, reproducibility and clinicopathological correlates. Am J Transplant 2008; 8: 819-825. (Pubitemid 351347749)
42. Feucht HE, Schneeberger H, Hillebrand G, et al,. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-1338. (Pubitemid 23161421)
43. Loupy A, Suberbielle-Boissel C, Hill GS, et al,. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.